SG11201801756WA - Novel peptides and combination of peptides for use in immunotherapy against various cancers - Google Patents
Novel peptides and combination of peptides for use in immunotherapy against various cancersInfo
- Publication number
- SG11201801756WA SG11201801756WA SG11201801756WA SG11201801756WA SG11201801756WA SG 11201801756W A SG11201801756W A SG 11201801756WA SG 11201801756W A SG11201801756W A SG 11201801756WA SG 11201801756W A SG11201801756W A SG 11201801756WA SG 11201801756W A SG11201801756W A SG 11201801756WA
- Authority
- SG
- Singapore
- Prior art keywords
- peptides
- international
- december
- pct
- combination
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 9
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 8
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 238000009169 immunotherapy Methods 0.000 title abstract 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 230000005975 antitumor immune response Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8135—Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0091—Oxidoreductases (1.) oxidizing metal ions (1.16)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1264—DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y116/00—Oxidoreductases oxidizing metal ions (1.16)
- C12Y116/01—Oxidoreductases oxidizing metal ions (1.16) with NAD+ or NADP+ as acceptor (1.16.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07031—DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal deoxynucleotidyl transferase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Theoretical Computer Science (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau res., 00) (43) International Publication Date ..... ..sr ,„,„.1 15 June 2017(15.06.2017) WIPO I PCT ID Hit (10) WO 111111111111111111IIIIIIII International II 2017/097699 III IIIIIIIIIIIIIII Publication IIIIIIIIIIIIII Al Number RIO IIII IIIIIIII (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every CO7K 7/06 (2006.01) A61K 38/04 (2006.01) kind of national protection available): AE, AG, AL, AM, CO7K 7/08 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP2016/079737 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 5 December 2016 (05.12.2016) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (26) Publication Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 1521894.4 11 December 2015 (11.12.2015) GB (84) Designated States (unless otherwise indicated, for every 62/266,233 11 December 2015 (11.12.2015) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: IMMATICS BIOTECHNOLOGIES GMBH TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, [DE/DE]; Paul-Ehrlich-Strasse 15, 72076 Tuebingen (DE). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (72) Inventors: MAHR, Andrea; Kirschenweg 22, 72076 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Tubingen (DE). WEINSCHENK, Toni; Im Morgenrain LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, 15, 73773 Aichwald (DE). SONG, Colette; Wil- li-Baumeister-Weg 21, 73760 Ostfildern (DE). SCHOOR, GW, KM, ML, MR, NE, SN, TD, TG). Oliver; Eichhaldenstrasse 19, 72074 Tilbingen (DE). Published: FRITSCHE, Larchenweg 11, Dussligen Jens; 72144 21(3)) with international search report (Art SINGH, Harpreet; 2215 Dryden Rd, Houston, (DE). Texas 77030 (US). — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of (74) Agent: BOEHMERT & BOEHMERT; KRAUSS Jan B., amendments (Rule 48.2(h)) Pettenkoferstrasse 20 - 22, 80336 Munich (DE). — with sequence listing of description (Rule 5.2(a)) part Il .4t Cr \ Cr \ !h . ' 0 \ (54) Title: NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS O CANCERS Ir --- (57) : The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In Il c:::, particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associ - el ated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active phar- 0 maceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562266233P | 2015-12-11 | 2015-12-11 | |
GBGB1521894.4A GB201521894D0 (en) | 2015-12-11 | 2015-12-11 | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
PCT/EP2016/079737 WO2017097699A1 (en) | 2015-12-11 | 2016-12-05 | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201801756WA true SG11201801756WA (en) | 2018-06-28 |
Family
ID=55274600
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201801756WA SG11201801756WA (en) | 2015-12-11 | 2016-12-05 | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
SG10202101368WA SG10202101368WA (en) | 2015-12-11 | 2016-12-05 | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202101368WA SG10202101368WA (en) | 2015-12-11 | 2016-12-05 | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
Country Status (18)
Country | Link |
---|---|
US (15) | US20170189504A1 (en) |
EP (1) | EP3325498A1 (en) |
JP (2) | JP7229516B2 (en) |
KR (1) | KR20180085725A (en) |
CN (1) | CN108602854A (en) |
AU (1) | AU2016368433B2 (en) |
BR (1) | BR112018008806A2 (en) |
CA (1) | CA3007382A1 (en) |
CR (1) | CR20180245A (en) |
EA (1) | EA201891116A1 (en) |
GB (1) | GB201521894D0 (en) |
MA (3) | MA43490A1 (en) |
MX (1) | MX2018005374A (en) |
PE (1) | PE20181316A1 (en) |
PH (1) | PH12018500551A1 (en) |
SG (2) | SG11201801756WA (en) |
TW (1) | TWI689516B (en) |
WO (1) | WO2017097699A1 (en) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017083525A1 (en) | 2015-11-11 | 2017-05-18 | Opi Vi- Ip Holdco Llc | Composition and methods for anti-tnfr2 antibodies |
GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
PE20230343A1 (en) * | 2015-12-11 | 2023-03-01 | Immatics Biotechnologies Gmbh | PEPTIDES THAT STIMULATE ANTI-TUMORAL IMMUNE RESPONSES |
MA44524A (en) * | 2016-03-31 | 2019-02-06 | Neon Therapeutics Inc | NEOANTIGENS AND THEIR METHODS OF USE |
JP7075125B2 (en) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | A novel peptide, peptide combination as a target and for use in immunotherapy for gallbladder cancer and cholangiocarcinoma and other cancers |
GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
DE102016123893A1 (en) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T cell receptors with improved binding |
EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
TW201841937A (en) | 2017-04-10 | 2018-12-01 | 德商英麥提克生物技術股份有限公司 | Novel peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
MA49123A (en) | 2017-04-10 | 2020-03-25 | Immatics Biotechnologies Gmbh | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIA AND OTHER CANCERS |
GB201709866D0 (en) * | 2017-06-20 | 2017-08-02 | Immunocore Ltd | T cell receptors |
DE102017114737A1 (en) | 2017-06-30 | 2019-01-03 | Immatics Biotechnologies Gmbh | New T cell receptors and their use in immunotherapy |
SG11202000027WA (en) | 2017-07-14 | 2020-02-27 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
CA3080835A1 (en) * | 2017-10-31 | 2019-05-09 | Pantarhei Bioscience B.V. | Immunotherapeutic methods for treating and/or preventing lung cancer |
DE102017127984B4 (en) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Method for the propagation and activation of γδ T cells |
US10692605B2 (en) | 2018-01-08 | 2020-06-23 | International Business Machines Corporation | Library screening for cancer probability |
CN111684062A (en) | 2018-02-09 | 2020-09-18 | 伊玛提克斯美国公司 | Method for producing T cell |
DE102018107224A1 (en) * | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptides and combinations of peptides of non-canonical origin for use in immunotherapy against various cancers |
TW202016131A (en) * | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | Peptides for use in immunotherapy against cancers |
TW202019955A (en) * | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | Immunotherapy with b*07 restricted peptides and combination of peptides against cancers and related methods |
US20210317165A1 (en) * | 2018-09-03 | 2021-10-14 | Laboratoire Hra-Pharma | Zp3 fragments in immunotherapy of ovarian cancer |
MX2021003051A (en) * | 2018-09-14 | 2021-05-27 | Immatics Biotechnologies Gmbh | Method for high throughput peptide-mhc affinity screening for tcr ligands. |
TW202024121A (en) * | 2018-09-18 | 2020-07-01 | 德商英麥提克生物技術股份有限公司 | Immunotherapy with a*01 restricted peptides and combination of peptides against cancers and related methods |
JP7216995B2 (en) * | 2018-12-05 | 2023-02-02 | 学校法人関西医科大学 | Thymic carcinoma biomarkers and prognostic markers for thymic tumors |
US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
EA202193139A1 (en) | 2019-05-27 | 2022-03-01 | Имматикс Юс, Инк. | VIRAL VECTORS AND THEIR APPLICATIONS IN ADOPTIONAL CELL THERAPY |
KR20220018006A (en) | 2019-06-06 | 2022-02-14 | 이매틱스 바이오테크놀로지스 게엠베하 | Classification by counter selection using sequence-like peptides |
CN114174323A (en) * | 2019-07-05 | 2022-03-11 | 弗朗西斯·克里克研究所有限公司 | Novel cancer antigens and methods |
US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
IL295891A (en) | 2020-02-24 | 2022-10-01 | Immatics Us Inc | Methods for expanding t cells for the treatment of cancer and related malignancies |
DE102020111571A1 (en) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | WPRE MUTANT CONSTRUCTS, COMPOSITIONS, AND RELATED PROCEDURES |
DE102020106710A1 (en) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | WPRE MUTANT CONSTRUCTS, COMPOSITIONS, AND RELATED PROCEDURES |
WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
CN113416253B (en) * | 2021-05-24 | 2022-12-13 | 复旦大学 | Isolated antigen ITPRIPL1 binding proteins and uses thereof |
JP2024502034A (en) | 2020-12-31 | 2024-01-17 | イマティクス ユーエス,アイエヌシー. | CD8 polypeptides, compositions, and methods of using them |
BR112023022975A2 (en) | 2021-05-05 | 2024-01-23 | Immatics Biotechnologies Gmbh | IMPROVED BMA031 ANTIGEN BINDING POLYPEPTIDES |
EP4337955A1 (en) * | 2021-05-13 | 2024-03-20 | La Jolla Institute for Immunology | Coronavirus t cell epitopes, megapools and uses thereof |
WO2023025851A1 (en) | 2021-08-24 | 2023-03-02 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
TW202332765A (en) | 2021-09-20 | 2023-08-16 | 美商英麥提克斯股份有限公司 | Monocyte depletion of t cells populations for t-cell therapy |
WO2023081925A1 (en) | 2021-11-08 | 2023-05-11 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
WO2023148333A1 (en) | 2022-02-03 | 2023-08-10 | CeCaVa GmbH & Co. KG | Co-vaccination with cd4 and cd8 antigens |
CN114736298B (en) * | 2022-04-08 | 2023-12-12 | 陕西脉元生物科技有限公司 | Anti-shrom 2 autoantibody for detecting autoimmune system diseases, and product and application thereof |
US20240066127A1 (en) | 2022-04-28 | 2024-02-29 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
US20230348561A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
WO2023212697A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
CN115785204B (en) * | 2022-06-10 | 2024-02-13 | 河北博海生物工程开发有限公司 | Lung cancer specific molecular target 08 and application thereof |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1118860A1 (en) * | 2000-01-21 | 2001-07-25 | Rijksuniversiteit te Leiden | Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes |
AUPQ776100A0 (en) * | 2000-05-26 | 2000-06-15 | Australian National University, The | Synthetic molecules and uses therefor |
US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US20030118585A1 (en) | 2001-10-17 | 2003-06-26 | Agy Therapeutics | Use of protein biomolecular targets in the treatment and visualization of brain tumors |
NZ573740A (en) | 2001-09-18 | 2010-07-30 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor, particularly kidney tumor - TAT184 |
WO2004048549A2 (en) | 2002-11-26 | 2004-06-10 | Cold Spring Harbor Laboratory | Dep-1 receptor protein tyrosine phosphatase interacting proteins and related methods |
CN1253469C (en) * | 2003-11-28 | 2006-04-26 | 北京大学 | Antigenic determinant polypeptide of human tumor-testis antigen HCA587 and use thereof |
US7399469B2 (en) | 2004-03-26 | 2008-07-15 | Pdl Biopharma, Inc. | Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer |
US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
JP2008536480A (en) | 2005-02-17 | 2008-09-11 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | Compositions, kits, and methods for cancer identification, evaluation, prevention, and treatment, and methods of cancer treatment |
US7608413B1 (en) | 2005-03-25 | 2009-10-27 | Celera Corporation | Kidney disease targets and uses thereof |
US7842467B1 (en) | 2005-05-12 | 2010-11-30 | Celera Corporation | Breast disease targets and uses thereof |
US7504225B2 (en) * | 2005-05-12 | 2009-03-17 | Applied Genomics, Inc. | Reagents and methods for use in cancer diagnosis, classification and therapy |
WO2007056523A2 (en) | 2005-11-08 | 2007-05-18 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods for diagnosing and monitoring the progression of cancer |
US7358231B1 (en) | 2005-12-01 | 2008-04-15 | Applera Corporation | Pancreatic cancer secreted targets and uses thereof |
WO2008021290A2 (en) | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
US7910565B2 (en) * | 2006-09-01 | 2011-03-22 | Wisconsin Alumni Research Foundation | Prostate cancer vaccine |
CN101066991A (en) * | 2007-06-13 | 2007-11-07 | 北京大学 | Antigenic determinant polypeptide of human tumor-testis antigen HCA587 and its application |
US8080634B2 (en) | 2007-07-27 | 2011-12-20 | Immatics Biotechnologies Gmbh | Immunogenic epitope for immunotherapy |
US7960134B1 (en) | 2007-08-01 | 2011-06-14 | Arqule, Inc. | Kinase inhibition models and their uses |
US7892770B2 (en) | 2007-08-24 | 2011-02-22 | Van Andel Research Institute | Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods |
WO2009036246A2 (en) * | 2007-09-14 | 2009-03-19 | Immunotope, Inc. | Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer |
GB0721686D0 (en) * | 2007-11-05 | 2007-12-12 | Medinnova As | Polypeptides |
US8455623B2 (en) | 2008-05-21 | 2013-06-04 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
WO2012178087A1 (en) | 2011-06-22 | 2012-12-27 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of bladder cancer |
NL2007536C2 (en) * | 2011-10-05 | 2013-04-08 | Academisch Ziekenhuis Leiden Lumc | Adjuvant compound. |
CA2898474A1 (en) * | 2013-02-14 | 2014-08-21 | Immunocellular Therapeutics, Ltd. | Cancer vaccines and vaccination methods |
TWI777197B (en) | 2013-08-05 | 2022-09-11 | 德商伊瑪提克斯生物科技有限公司 | Novel peptides, cells, and their use against several tumors, methods for production thereof and pharmaceutical composition comprising the same |
GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
GB201408255D0 (en) | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
GB201520595D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
EP3383418B1 (en) * | 2015-12-04 | 2021-10-20 | Board of Regents, The University of Texas System | Slc45a2 peptides for immunotherapy |
-
2015
- 2015-12-11 GB GBGB1521894.4A patent/GB201521894D0/en not_active Ceased
-
2016
- 2016-12-05 EA EA201891116A patent/EA201891116A1/en unknown
- 2016-12-05 MX MX2018005374A patent/MX2018005374A/en unknown
- 2016-12-05 PE PE2018000553A patent/PE20181316A1/en unknown
- 2016-12-05 SG SG11201801756WA patent/SG11201801756WA/en unknown
- 2016-12-05 EP EP16805839.4A patent/EP3325498A1/en active Pending
- 2016-12-05 MA MA43490A patent/MA43490A1/en unknown
- 2016-12-05 SG SG10202101368WA patent/SG10202101368WA/en unknown
- 2016-12-05 CN CN201680072386.4A patent/CN108602854A/en active Pending
- 2016-12-05 KR KR1020187014106A patent/KR20180085725A/en unknown
- 2016-12-05 JP JP2018519334A patent/JP7229516B2/en active Active
- 2016-12-05 WO PCT/EP2016/079737 patent/WO2017097699A1/en active Application Filing
- 2016-12-05 AU AU2016368433A patent/AU2016368433B2/en active Active
- 2016-12-05 BR BR112018008806-4A patent/BR112018008806A2/en active Search and Examination
- 2016-12-05 MA MA042494A patent/MA42494A/en unknown
- 2016-12-05 CA CA3007382A patent/CA3007382A1/en active Pending
- 2016-12-05 MA MA42073A patent/MA42073A1/en unknown
- 2016-12-05 CR CR20180245A patent/CR20180245A/en unknown
- 2016-12-09 US US15/374,415 patent/US20170189504A1/en not_active Abandoned
- 2016-12-09 US US15/374,882 patent/US10179165B2/en active Active
- 2016-12-09 US US15/374,452 patent/US10143730B2/en active Active
- 2016-12-09 US US15/375,051 patent/US10279022B2/en active Active
- 2016-12-09 US US15/375,047 patent/US10098938B2/en active Active
- 2016-12-09 US US15/374,975 patent/US10058598B2/en active Active
- 2016-12-09 US US15/375,017 patent/US10967053B2/en active Active
- 2016-12-09 US US15/375,058 patent/US10117917B2/en active Active
- 2016-12-09 US US15/375,037 patent/US10143731B2/en active Active
- 2016-12-09 US US15/374,912 patent/US20170189507A1/en not_active Abandoned
- 2016-12-09 US US15/374,993 patent/US10004792B2/en active Active
- 2016-12-09 US US15/375,030 patent/US10098937B2/en active Active
- 2016-12-09 TW TW105140777A patent/TWI689516B/en active
-
2018
- 2018-03-14 PH PH12018500551A patent/PH12018500551A1/en unknown
- 2018-08-21 US US16/106,962 patent/US10314897B2/en active Active
- 2018-08-21 US US16/106,951 patent/US10314896B2/en active Active
- 2018-08-29 US US16/116,323 patent/US10342859B2/en active Active
-
2021
- 2021-04-02 JP JP2021063261A patent/JP2021104045A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201801756WA (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers | |
SG11201801384YA (en) | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | |
SG11201801670YA (en) | Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers | |
SG11201806577UA (en) | Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers | |
SG11201806951TA (en) | Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers | |
SG11201807300PA (en) | Uterine cancer treatments | |
SG11201806905UA (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
SG11201807590SA (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
SG11201906198PA (en) | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | |
SG11201809781PA (en) | Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers | |
SG11201807868VA (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
SG11201808629UA (en) | Immunotherapy against melanoma and other cancers | |
SG11201909153UA (en) | Peptides and combination thereof for use in the immunotherapy against cancers | |
SG11201804178YA (en) | Pd1 and/or lag3 binders | |
SG11201810076WA (en) | Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety | |
SG11201900955VA (en) | T cell receptors and immune therapy using the same | |
SG11201907580SA (en) | Combination therapies for treatment of bcma-related cancers and autoimmune disorders | |
SG11201808783XA (en) | Cd80 variant immunomodulatory proteins and uses thereof | |
SG11201909058WA (en) | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers | |
SG11201908527SA (en) | High affinity mage-a1-specific tcrs and uses thereof | |
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201808797XA (en) | T cell receptors | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof |